News articles
-
Blood Tests: Not Just for the Impaired?
In memory clinics and in research cohorts, immunoassays for plasma markers can now distinguish people who have Alzheimer’s disease... Read more... -
Looking Good: Immunoassays for Blood Markers
For years, scientists have been working toward blood tests for Alzheimer’s disease that could be used routinely in clinical... Read more... -
More opportunities to test for Alzheimer’s using new analytical method
A simpler method of analysing blood samples for Alzheimer’s disease has been tested in a large multicentre study, led... Read more... -
Simple, yet effective way to early detect Alzheimer’s disease
A simpler method of analysing blood samples for Alzheimer’s disease has been tested in a large multicentre study, led... Read more... -
How dementia affects the brain’s ability to empathize
Patients with frontotemporal dementia often lack the ability to feel empathy. A study at Lund University and the Karolinska... Read more... -
Reading the signs of dementia
In this Nature outlook the BioFINDER study group’s work on how blood tests are leading to earlier diagnosis, and... Read more...
Recent key publications
Plasma phospho-tau217 for Alzheimer’s disease diagnosis in primary and secondary care using a fully automated platform
Plasma MTBR-tau243 biomarker identifies tau tangle pathology in Alzheimer’s disease
Plasma p-tau217 and tau-PET predict future cognitive decline among cognitively unimpaired individuals: implications for clinical trials
Machine learning prediction of tau‐PET in Alzheimer’s disease using plasma, MRI, and clinical data
Alpha-synuclein seed amplification assay longitudinal outcomes in Lewy body disease spectrum.
Altered Empathy Processing in Frontotemporal Dementia.
Diagnosis of Alzheimer’s disease using plasma biomarkers adjusted to clinical probability.
A comprehensive head-to-head comparison of key plasma phosphorylated tau 217 biomarker tests.
Lewy body pathology exacerbates brain hypometabolism and cognitive decline in Alzheimer’s disease.
Blood Biomarkers to Detect Alzheimer Disease in Primary Care and Secondary Care
Plasma Phosphorylated Tau 217 and Aβ42/40 to Predict Early Brain Aβ Accumulation in People Without Cognitive Impairment
MRI Signature of α-Synuclein Pathology in Asymptomatic Stages and a Memory Clinic Population
Revised criteria for the diagnosis and staging of Alzheimer’s disease
Disease progression modelling reveals heterogeneity in trajectories of Lewy-type α-synuclein pathology
Tau Positron Emission Tomography for Predicting Dementia in Individuals With Mild Cognitive Impairment
Disease staging of Alzheimer’s disease using a CSF-based biomarker model
A blood-based biomarker workflow for optimal tau-PET referral in memory clinic settings
Highly Accurate Blood Test for Alzheimer’s Disease Comparable or Superior to Clinical CSF Tests.
Plasma Biomarker Strategy for Selecting Patients With Alzheimer Disease for Antiamyloid Immunotherapies.
The α-synuclein PET tracer [18F] ACI-12589 distinguishes multiple system atrophy from other neurodegenerative diseases.
DOPA decarboxylase is an emerging biomarker for Parkinsonian disorders including preclinical Lewy body disease.
Cognitive effects of Lewy body pathology in clinically unimpaired individuals.
Clinical effects of Lewy body pathology in cognitively impaired individuals.
CSF MTBR-tau243 is a specific biomarker of tau tangle pathology in Alzheimer’s disease.
